ReShape Lifesciences

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. The company was founded in December 2002 and is headquartered in San Clemente, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.

SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System

Akebia Therapeutics

Celularity

MGO Global Inc

Penny stocks to watch with news this week. Are they a buy now or should you avoid them entirely?

Penny Stocks To Buy? 4 To Watch Now After Big News This Week

SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled for 8:00 am ET on March 29, 2022. The delay is required to allow the company additional time to complete its year end audited financial information.

ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call

Top Industry Experts in Bariatric Surgery and Obesity Will Help Solidify ReShape's Position as the Premier Physician-Led Weight Loss and Metabolic Health Solutions Company Top Industry Experts in Bariatric Surgery and Obesity Will Help Solidify ReShape's Position as the Premier Physician-Led Weight Loss and Metabolic Health Solutions Company

ReShape Lifesciences Announces Formation of International Scientific Advisory Board

Conference Call to be Held at 8:00 am ET on Wednesday, March 29, 2023 Conference Call to be Held at 8:00 am ET on Wednesday, March 29, 2023

ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update

SAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q2 Virtual Investor Summit on Wednesday, March 29 at 1:00 pm ET. During the virtual presentation, management will highlight the Company's three pillars for growth and its portfolio of products that address the entire weight loss continuum including the anatomy-sparing Lap-Band®.

ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit

Ault Alliance Inc

FuboTV

Lyft

Wish

Exela Technologies

XPeng

Let's face it – there are some stocks to sell that just have no hope left. Hope is a great thing.

7 Stocks That Just Have No Hope Left

SAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit was sold at a public offering price of $8.00. The warrants in the units are immediately exercisable at a price of $8.00 per share and expire five years from the date of issuance. Alternatively, each warrant will become exercisable for 0.75 shares of common stock under the cashless exercise provision included in the common warrants rather than the 1.5 shares of common stock under the cash exercise provision. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.

ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering

ReShape Lifesciences (NASDAQ: RSLS ) stock is falling hard on Monday as the company's shares pull back from a rally on Friday. RSLS stock saw a massive gain on Friday that had it finishing out normal trading hours more than 170% higher.

Why Is ReShape Lifesciences (RSLS) Stock Down 63% Today?

SAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit is being sold at a public offering price of $8.00. The warrants in the units will be immediately exercisable at a price of $8.00 per share and will expire five years from the date of issuance. Alternatively, each warrant will become exercisable for 0.75 shares of common stock under the cashless exercise provision included in the common warrants rather than the 1.5 shares of common stock under the cash exercise provision. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering

One of the biggest movers in today's session, Reshape Lifesciences (NASDAQ: RSLS ) is absolutely skyrocketing. At the time of writing, RSLS stock has surged an impressive 150% in today's session alone.

5 Investors Betting Big on Reshape Lifesciences (RSLS) Stock

Reshape Lifesciences (NASDAQ: RSLS ) stock is rocketing higher on Friday as a filing mixup shines a light on the company's shares. According to a filing with the U.S. Securities and Exchange Commission (SEC), Reshape Lifesciences is seeking the withdrawal of two filings made with the agency on Thursday.

Why Is Reshape Lifesciences (RSLS) Stock Up 136% Today?

SAN CLEMENTE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-50 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on December 23, 2022. At that time, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share. In connection with the reverse stock split, the company also increased the number of shares of common stock that it is authorized to issue under its certificate of incorporation to 300 million shares. The number of authorized shares of common stock and preferred stock under the company's certificate of incorporation will not be reduced in connection with the reverse stock split.

ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022

ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Paula Schwartz - Managing Director-Rx Communications Group Paul Hickey - President & Chief Executive Officer Thomas Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Ben Haynor - AGP Operator Good morning and thank you for joining the ReShape Lifesciences Third Quarter 2022 Conference Call. I would now like to turn the call over to Paula Schwartz from Rx Communications.

ReShape Lifesciences Inc. (RSLS) Q3 2022 Earnings Call Transcript

Conference Call to be Held at 8:00 am ET Today Conference Call to be Held at 8:00 am ET Today

ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN CLEMENTE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale in a registered direct offering of 2,884,615 shares of the Company's common stock (or common stock equivalents in the form of pre-funded warrants) at a purchase price of $0.26 per share and 2,500 shares of series D mirroring preferred stock (“Series D Preferred Stock”) and, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 2,884,615 shares of common stock. Each share of Series D Preferred Stock has a stated value of $0.001 per share and will automatically terminate on the date that the Company effects a reverse stock split of the Company's shares of common stock or, if later, the date the Company effects an increase in its authorized shares of common stock. The warrants have an exercise price of $0.30 per share, will become exercisable six months following the date of issuance and will expire five and one-half years following the date of issuance. The closing of the offering is expected to occur on or about November 9, 2022, subject to the satisfaction of customary closing conditions.

ReShape Lifesciences Announces $750,000 Registered Direct Offering

Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022 Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022

ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q4 Investor Summit on Monday, November 14 at 1:30 p.m. ET. During the presentation, management will highlight its next-generation, anatomy-sparing, Lap-Band® program and the nationwide, reshapecare™ virtual health coaching program.

ReShape Lifesciences to Present at the Q4 Investor Summit

Lap-Band® is the Only FDA Approved Device Indicated for Weight Reduction in Patients With a Body Mass Index (BMI) of at Least 40 kg/m 2 or a BMI of at least 30 kg/m 2 With One or More Obesity-Related Comorbidities

ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

Active ASMBS Members, Comprised of Lap-Band® Clinical Experts, Participated in a Consensus Process to Yield Recommendations for Optimal Aftercare

ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)

$300,000 Grant will Fund Additional Research for the Treatment of Hypoglycemia $300,000 Grant will Fund Additional Research for the Treatment of Hypoglycemia

ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President Global Sales for Enteromedics, the predecessor company to Reshape, will be responsible for strengthening the executional efficiencies of the sales and marketing team, worldwide. In this role, he will report directly to Mr. Paul F. Hickey, ReShape's President and Chief Executive Officer.

ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Michael Miller - Rx Communications, Investor Relations Paul Hickey - President and Chief Executive Officer Tom Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon. Thank you for joining the ReShape Lifesciences Second Quarter 2022 Conference Call.

ReShape Lifesciences Inc. (RSLS) CEO Paul Hickey on Q2 2022 Results - Earnings Call Transcript

Second Quarter Revenues Increased 19% Sequentially, Indicating DTC Campaign Continues to Drive Demand for Lap-Band® Procedures

ReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022 Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022

News for ReShape Lifesciences Stock (RSLS)